Amphista Therapeutics Limited

Amphista Therapeutics is a leading next-generation targeted protein degradation (TPD) company dedicated to developing innovative therapies with significantly improved efficacy. Their proprietary Eclipsys™ Drug Development platform rapidly expands the therapeutic applications of this transformational modality, enabling them to develop a portfolio of innovative therapeutic candidates from early stage discovery to clinical stage research and commercialization. Their approach is guided by the mission to unlock the full therapeutic potential of TPD and make a positive difference for patients.

Amphista has assembled a world-leading group of scientists and business leaders, driven by their employee-led values of impact, integrity, communication, quality and science, growth and innovation, and teamwork. They are looking for dedicated and passionate individuals who wish to contribute to their mission of unlocking the full therapeutic potential of TPD. Their global operations and progress are guided by their commitment to developing drugs to bring life-changing medicines to patients.

Amphista Therapeutics is a leading company in the development of next-generation targeted protein degradation (TPD) therapies. They are driven by a mission to unlock the full therapeutic potential of TPD, create a new generation of innovative therapies with significantly improved efficacy, and ultimately make a positive difference for patients suffering from severe diseases, including cancer and neurodegenerative diseases.

Amphista Therapeutics fosters a fast-paced, collaborative environment driven by a shared commitment to innovation and making a positive impact on patients' lives. Their website highlights their dedication to scientific excellence and emphasizes the value of team work, communication, integrity, and growth. They actively encourage their employees to contribute their unique skills and passions, making Amphista a place where individuals can thrive and contribute to the development of groundbreaking TPD therapies.